Showing 61-70 of 822 results for "".
New Drugs for Dry Eye and Demodex Blepharitis
https://modernod.com/topics/ocular-surface/new-drugs-for-dry-eye-and-idemodexi-blepharitis/38625/More options, more personalized treatment for patients. Get familiar with what may end up in your toolbox.The Macular Degeneration Association
https://modernod.com/topics/retina/the-macular-degeneration-association/38199/Empowering patients and their caregivers to live fuller lives.Biomarkers and Second-Generation Treatments
https://modernod.com/specialty/optometry/Biomarkers-and-Second-Generation-Treatments-2506/29467/Drs. Kitchens and LeMay review biomarkers used in recognizing and treating AMD and highlights of two case studies.What’s New in Dry Eye Management?
https://modernod.com/topics/ocular-surface/whats-new-in-dry-eye-management/38765/A look at our growing list of options.Tools and Techniques for Managing MGD
https://modernod.com/topics/ocular-surface/tools-and-techniques-for-managing-mgd/39022/What’s available—and what’s coming.Presbyopia-Correcting Drops: The Importance of Patient Selection
https://modernod.com/cme/ophthalmology/Presbyopia-Correcting-Drops-The-Importance-of-Patient-Selection-2508/29739/Learn more about presbyopia-correcting drops and the types of patients who may be ideal candidates as well as those who require more caution.The Trouble With the Term “ECP”
https://modernod.com/mod-issues/2025-mar-apr/the-trouble-with-the-term-ecp/38943/Is this really the best way to refer to eye doctors?Much Ado About the Ocular Surface
https://modernod.com/topics/ocular-surface/much-ado-about-the-ocular-surface/38762/The Role of Presbyopia-Correcting Drops
https://modernod.com/cme/ophthalmology/The-Role-of-Presbyopia-Correcting-Drops-2508/29737/Learn about miotics and how they work for presbyopia correction, especially for certain patients who are not ready for surgical options.The Near Future in Managing Dry Eye Disease
https://modernod.com/mod-issues/marchapril-2025-supplement/the-near-future-in-managing-dry-eye-disease/38940/A closer look at the biggest challenges in treating DED and what’s in the pipeline.